Plexāā has launched BLOOM 43, a wearable medical device designed to reduce complications in breast surgery. The device, which launched in the United States earlier this month, uses thermal preconditioning to prepare skin and tissue before procedures.
Wound complications occur in up to 30% of breast reconstruction or implant procedures, often requiring antibiotics, hospitalization, or additional surgery. BLOOM 43 addresses this by heating the skin at the surgical site to stimulate heat shock proteins, which enhance blood flow and tissue resilience. Patients wear the device at home, typically the night before surgery.
Clinical trials demonstrated that the technology decreased the absolute risk of skin necrosis by 24% and reduced required follow-up surgeries by 50%. Patients also experienced hospital stays shortened by two days and 70% fewer outpatient follow-ups.
The device includes a companion app that provides preoperative guidance on nutrition and physical health. The app is certified by DHAF and ORCHA and available globally through the App Store and Google Play.
BLOOM 43 is being prescribed at San Francisco Plastic Surgery & Laser Center and Illuminate Surgery in Los Gatos, California. The device is available for hospitals, surgical centers, and clinics across the United States, and patients can order directly through the app with a prescription. The device qualifies for HSA and FSA reimbursement.
Plexāā was founded by plastic surgeon Saahil Mehta, MD, FRCS, and is exploring applications of the technology for C-sections, joint operations, and general and vascular surgery.
